Ceftriaxone + Sulbactam in pharma franchise in Punjab

Ceftriaxone + Sulbactam in PCD pharma franchise in Bhopal

Ceftriaxone + Sulbactam in top pharma company in Ghaziabad

Ceftriaxone + Sulbactam in pcd pharma supplier in Vijayawada

Ceftriaxone + Sulbactam in phama franchise company in India
Ceftriaxone + Sulbactam in phama distributor in Mangalore

Home/Products /ceftriaxone-1000mg-sulbactam-500mg-injection

Fritcet S 1.5g Injection

Composition : Ceftriaxone (1000mg) + Sulbactam (500mg)

Dosage Form : Injection

Packaging Type : Vial

Packaging : 1500 mg

Price : ₹214/-

Fritcet S 1.5g Injection is a combination antibiotic therapy designed to combat a range of bacterial infections. This formulation includes 1000 mg of ceftriaxone, a broad-spectrum cephalosporin antibiotic, and 500 mg of sulbactam, a beta-lactamase inhibitor. Together, they provide effective treatment against both Gram-positive and Gram-negative bacteria, making Fritcet S an ideal choice for serious infections such as pneumonia, skin infections, urinary tract infections, and intra-abdominal infections.

Ceftriaxone works by inhibiting bacterial cell wall synthesis, leading to cell lysis and death. Sulbactam enhances the efficacy of ceftriaxone by preventing the breakdown of the antibiotic by beta-lactamase enzymes produced by resistant bacteria. This synergy allows for effective treatment where monotherapy may fail.

Read More

About the Product

Fritcet S 1.5g Injection is a combination antibiotic therapy designed to combat a range of bacterial infections. This formulation includes 1000 mg of ceftriaxone, a broad-spectrum cephalosporin antibiotic, and 500 mg of sulbactam, a beta-lactamase inhibitor. Together, they provide effective treatment against both Gram-positive and Gram-negative bacteria, making Fritcet S an ideal choice for serious infections such as pneumonia, skin infections, urinary tract infections, and intra-abdominal infections.

Ceftriaxone works by inhibiting bacterial cell wall synthesis, leading to cell lysis and death. Sulbactam enhances the efficacy of ceftriaxone by preventing the breakdown of the antibiotic by beta-lactamase enzymes produced by resistant bacteria. This synergy allows for effective treatment where monotherapy may fail.

Common side effects may include gastrointestinal disturbances, rash, allergic reactions, and changes in blood parameters. Serious adverse effects are rare but can include severe allergic reactions and Clostridium difficile-associated diarrhea.

Fritcet S is indicated for the treatment of complicated infections caused by susceptible bacteria, including those in the respiratory tract, urinary tract, skin, and soft tissues.

Before administering Fritcet S, assess the patient's allergy history, especially related to penicillins or cephalosporins. Monitor renal function and ensure proper hydration during treatment. Fritcet S 1.5g Injection is administered intravenously or intramuscularly, with dosage adjustments based on the severity of infection and renal function. It is essential to complete the full course of therapy to prevent the development of antibiotic resistance. Regular monitoring by healthcare professionals is advised to ensure efficacy and safety throughout the treatment period.

Store at controlled room temperature, away from direct light and moisture. Keep out of reach of children.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our rapidly growing network of successful franchise partners and turn your ambitions into reality. Limited Territories Available — Don’t Miss Out!

Quick Navigation